NuVasive price target raised to $65 from $58 at Piper Jaffray Piper Jaffray analyst Matt O'Brien raised his price target for NuVasive to $65 from $58 after the company announced the completion of its acquisition of Biotronic. The analyst also increased his 2016 sales estimate by $27.1M and EPS by 4c, and his 2017 sales projection by $59M and EPS by 10c. Piper Jaffray has an Overweight rating on NuVasive's shares
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.